Xinyu Y. Mei
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: July 08, 2026
Lymph Node Yield and Disease-Free Survival After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective Cohort Study.
Journal: Annals of surgical oncology
Published: January 29, 2026
Survival Differences Among Non-pCR Patients with Distinct Pathological Outcomes After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
Journal: The Journal of thoracic and cardiovascular surgery
Published: January 22, 2026
Survival differences among patients with nonpathological complete response with distinct pathological outcomes after neoadjuvant therapy for esophageal squamous cell carcinoma.
Journal: The Journal of thoracic and cardiovascular surgery
Published: January 22, 2026
Association of immune-related adverse events with survival outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a national multicenter retrospective cohort study in China.
Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Published: November 04, 2025
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management.
Journal: The Journal of thoracic and cardiovascular surgery
Published: November 04, 2025
Correction: CD49a+ NK cells promote esophageal cancer development by inducing MDSCs infiltration via GM-CSF.
Journal: British journal of cancer
Published: October 06, 2025
Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study.
Journal: The Journal of thoracic and cardiovascular surgery
Published: August 02, 2025
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 21, 2025
Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study.
Journal: International journal of surgery (London, England)
Published: June 23, 2025
Borneol's Pre-Clinical Analgesic Efficacy: Mediated by Receptor and Immune Mechanisms.
Journal: Journal of pain research
Published: April 16, 2025
Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 30, 2025
Last Updated: 09/26/2026